SEARCH

SEARCH BY CITATION

References

  • 1
    Marth G, Yeh R, Minton M et al. Single-nucleotide polymorphisms in the public domain: how useful are they? Nat Genet 2001; 27: 3712.DOI: 10.1038/86864
  • 2
    Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 3429.
  • 3
    Evans WE & Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 48791.DOI: 10.1126/science.286.5439.487
  • 4
    Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 166771.
  • 5
    Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7: 2014.
  • 6
    Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 12005.
  • 7
    Lazarou JL. Reply. JAMA 1998; 280: 17431743.
  • 8
    Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 3016.
  • 9
    Green CF, Mottram DR, Rowe PH, Pirmohamed M. Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study. J Clin Pharm Ther 2000; 25: 35561.DOI: 10.1046/j.1365-2710.2000.00298.x
  • 10
    Mjörndal T, Boman Danell M, Bäckström M et al. Adverse drug reactions as a cause for admission to a clinic of internal medicine. Abstract EACPT3 JC 4 October, 1999;: 5656.
  • 11
    Marshall A. Getting the right drug into the right patient. Nat Biotechnol 1997; 15: 124952.
  • 12
    Kim RB, Leake B, Choo E et al. Identification of functionally important MDR1 variant alleles among African-American and caucasian subjects. Drug Met Rev 2000; 32: 199199.
  • 13
    Hoffmeyer S, Burk O, Von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 34738.
  • 14
    Cascorbi I, Gerloff T, Johne A et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 16974.
  • 15
    Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295302.
  • 16
    Glatt CE, DeYoung JA, Delgado S et al. Screening a large reference sample to identify very low frequency sequence variants: comparisons between two genes. Nat Genet 2001; 27: 4358.DOI: 10.1038/86948
  • 17
    Ronis MJJ, Lindros KO, Ingelman-Sundberg M. The CYP2E Subfamily. In: Ioannides C, ed. Cytochromes P450: Metabolic and Toxicological Aspects. New York: CRC Press, 1996; 211–39.
  • 18
    Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 106775.
  • 19
    Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 38391.DOI: 10.1038/86882
  • 20
    Fukuda T, Nishida Y, Imaoka S et al. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 2000; 380: 3038.DOI: 10.1006/abbi.2000.1936
  • 21
    Dahl-Puustinen ML, Liden A, Alm C, Nordin C, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 7881.
  • 22
    Sagar M, Bertilsson L, Stridsberg M, Kjellin A, Mardh S, Seensalu R. Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. Aliment Pharmacol Ther 2000; 14: 1495502.DOI: 10.1046/j.1365-2036.2000.00835.x
  • 23
    Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [see comments]. Lancet 1999; 353: 7179.
  • 24
    Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 18169.
  • 25
    Dalen P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 44452.
  • 26
    Dalen P, Dahl ML, Eichelbaum M, Bertilsson L, Wilkinson GR. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 1999; 9: 697706.
  • 27
    McLellan RA, Oscarson M, Seidegård J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7: 18791.
  • 28
    McLellan RA, Oscarson M, Alexandrie AK et al. Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. Mol Pharmacol 1997; 52: 95865.
  • 29
    Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 2001; 29: 915.
  • 30
    Rao Y, Hoffmann E, Zia M et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58: 74755.
  • 31
    Fonne-Pfister R, Bargetzi MJ, Meyer UA. MPTP, the neurotoxin inducing Parkinson’s disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987; 148: 114450.
  • 32
    Dalen P, Dahl M, Andersson K, Bertilsson L. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. Br J Clin Pharmacol 2000; 49: 1804.DOI: 10.1046/j.1365-2125.2000.00120.x
  • 33
    Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine’s oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000; 68: 3543.
  • 34
    Dalen P, Frengell C, Dahl ML, Sjoqvist F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997; 19: 5434.
  • 35
    Iyer L & Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer 1998; 34: 14939.
  • 36
    Vineis P, Malats N, Boffetta P. Chapter 1. Why study metabolic susceptibility to cancer? IARC Sci Publ 1999; 148: 13.
  • 37
    Spielberg SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996; 24: 50919.
  • 38
    Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001; 29: 6015.
  • 39
    Krynetski EY & Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 2000; 61: 13646.
  • 40
    Drews J & Ryser S. The role of innovation in drug development. Nat Biotechnol 1997; 15: 13189.
  • 41
    Liggett SB. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 2000; 61: 16773.
  • 42
    Drysdale CM, McGraw DW, Stack CB et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000; 97: 10 4838.
  • 43
    Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405: 85765.DOI: 10.1038/35015728
  • 44
    Erdmann J, Shimron-Abarbanell D, Rietschel M et al. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 1996; 97: 6149.DOI: 10.1007/s004390050104
  • 45
    Lin CH, Tsai SJ, Yu YW et al. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport 1999; 10: 5760.
  • 46
    Arranz MJ, Collier DA, Munro J et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 1996; 217: 1778.
  • 47
    Arranz AJ, Collier D, Kerwin RW. Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics 2001; 1: 310.
  • 48
    Kreek MJ. Opiates, opioids and addiction. Mol Psychiatry 1996; 1: 23254.
  • 49
    Roberts AJ, McDonald JS, Heyser CJ et al. mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 2000; 293: 10028.
  • 50
    Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single-nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 2000; 6: 66.
  • 51
    Ackerman MJ & Clapham DE. Ion channels – basic science and clinical disease. N Engl J Med 1997; 336: 157586.
  • 52
    Abbott GW, Sesti F, Splawski I et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97: 17587.
  • 53
    Sesti F, Abbott GW, Wei J et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 2000; 97: 10 6138.
  • 54
    Drazen JM, Yandava CN, Dube L et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22: 16870.DOI: 10.1038/9680
  • 55
    Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 13436.
  • 56
    Yoshida H, Mitarai T, Kawamura T et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy (see comments). J Clin Invest 1995; 96: 21629.
  • 57
    Van Essen GG, Rensma PL, De Zeeuw D et al. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996; 347: 945.
  • 58
    Benetos A, Cambien F, Gautier S et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996; 28: 10814.
  • 59
    O'Toole L, Stewart M, Padfield P, Channer K. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol 1998; 32: 98894.
  • 60
    Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338: 8693.
  • 61
    Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993; 261: 9213.
  • 62
    Poirier J, Delisle MC, Quirion R et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995; 92: 12 2604.
  • 63
    Miners JO & Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 52538.
  • 64
    Furuta T, Shirai N, Takashima M et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69: 15868.
  • 65
    Priori SG, Barhanin J, Hauer RN et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation 1999; 99: 51828.
  • 66
    Bernal ML, Sinues B, Johansson I et al. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 1999; 9: 65760.
  • 67
    Nishida Y, Fukuda T, Yamamoto I, Azuma J. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 2000; 10: 56770.
  • 68
    Garcia-Barcelo M, Chow LY, Lam KL, Chiu HF, Wing YK, Waye MM. Occurrence of CYP2D6 gene duplication in Hong Kong Chinese. Clin Chem 2000; 46: 14113.
  • 69
    Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 3429.
  • 70
    Ingelman-Sundberg M. Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. Drug Metab Rev 1999; 31: 44959.